Skip to Content

Generic Taytulla Availability

Taytulla is a brand name of ethinyl estradiol/norethindrone, approved by the FDA in the following formulation(s):

TAYTULLA (ethinyl estradiol; norethindrone acetate - capsule;oral)

  • Manufacturer: APIL
    Approval date: April 19, 2013
    Strength(s): 0.02MG;1MG [RLD]

Has a generic version of Taytulla been approved?

No. There is currently no therapeutically equivalent version of Taytulla available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Taytulla. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
    Patent 6,652,880
    Issued: November 25, 2003
    Inventor(s): Elizabeth Anne; Aylwin & Susan; Banbury & Josephine Joan Christine; Ferdinando & Henrik; de Nijs
    Assignee(s): R.P. Scherer Technologies, Inc.

    This invention is directed to pharmaceutical compositions for oral administration, wherein the drug or active ingredient is known to have stability problems associated with the use of free fatty acids. The compositions of the invention enhance the solubility of such compounds and improve the storage stability thereof and can be advantageously used in soft-gel and hard-shell capsular formulations. The liquid pharmaceutical compositions, according to the present invention, have a drug dissolved in a liquid vehicle. The liquid vehicle comprising a glyceride of a long chain fatty acid and a lypophilic surfactant having an HLB of less than ten. The composition, according to the invention, is also substantially free of free fatty acids.

    Patent expiration dates:

    • March 29, 2020
      Drug product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.